

# INDEX

- Advertising and trademarks, 11–12
- ANAQUA software, 157
- Arm’s-length pricing, 136
- Assets. *See also* Intellectual property and intangible assets (IP&IA)  
tangible vs. intangible, 4–5, 26, 144
- Assumed (virtual) transactions, 82, 186–188
- Assumptions  
in appraisals, 83  
assumed transactions, 82, 186–188  
in expected cash flow approach, 35  
Monte Carlo runs, 66  
in patent infringement, 186, 188  
in post-judgment royalty, 194
- Audits, 141–161. *See also*  
Management of IP assets;  
Royalty misreporting  
about the data presented, 130, 132–133  
agreements included, 154–155, 158–161  
assets included, 153–154, 158–161  
checklist for, 158–161  
definition, 144  
event-driven audits, 151–152  
frequency of, 146, 150–152  
general-purpose audits, 150–151  
how to do, 152–155  
limited-purpose focused audits, 152  
reasons for, 144–145  
results of, 145–146  
software for, 155–158  
of trade secrets, 14, 153–154, 160  
transfer price errors and, 136
- Bard Peripheral Vascular, Inc. v. W. L. Gore, Inc.*, 189, 195–198
- Base. *See* Royalty base
- Bayes, Thomas, 72
- Bayesian analysis, 63, 72–75
- Bayes’ theorem, 72
- Benchmarks and milestones  
*Royalty Rates for Technology*, 116  
unreported, 132, 133, 137
- Beta, 36–37, 41
- Biotechnology companies’ reasons for licensing, 17–19
- Biotechnology royalty rates, 121–128, 253–276  
aldurazyme, 254–256  
anti-hypertension therapy, 256–258  
attention deficit hyperactivity disorder, 258–259  
blood expander, 260–264  
cancer, 264–268  
corporate involvement, 122

- Biotechnology royalty rates  
 (*Continued*)  
 developmental stages of  
   technology, 126–128, 137,  
   253–254  
 exclusivity and, 21–22 (*see also*  
   Exclusivity)  
 key technologies, 125–126, 127  
 license fees, 124–125, 128  
 neurodegenerative and psychiatric  
   diseases therapy, 269–272  
 pain management, 272–273  
 per unit royalties, 123, 128  
 probability of success, 45  
 progesterone gel, 273–275  
 royalty percentages, 122–124,  
   128, 253–254  
*Royalty Rates for*  
   *Pharmaceuticals &*  
   *Biotechnology*, 21, 121, 253  
 spleen tyrosine kinase (Syk)  
   inhibitor, 275–276
- Black, Fischer, 76
- Black-Scholes option pricing model,  
 76–78
- Bose Corp. v. JBL, Inc.*, 165, 173
- Build-up method, 41–42
- Capital asset pricing model  
 (CAPM), 36–40
- Cash flows, risk adjusted.  
*See* Risk-adjusted cash flows
- Celebrity persona, 81–94  
 a building as celebrity, 83  
 Lanham Act amendment, 90  
 licensing of images, 85  
 new exploitations as new  
   property, 83–84  
 photography, 91–93
- right of privacy, 84–85  
 right of publicity, 85–87, 90,  
   91–93  
 as trademark, 87  
 value of, 81
- Coca-Cola and trade secrets, 14–15
- Cognitive biases, 78–79
- Collateral sales, 163–164, 182
- Commercialization of intellectual  
 property  
 developmental stages, 126–128,  
   137, 253–254  
 duration of protection, 23  
 infringement litigation, 6  
 internalized vs. licensed, 16  
 nonpracticing patent holders,  
   29–31, 193  
 revenue from, 4  
 software for, 157  
 valuation of economic benefits, 32
- Common-law marks, 154
- Competitive advantage  
 by business sector, 18  
 patented technology, 26  
 trade secrets and, 13–14, 18
- Computer programs. *See* Software
- Consumer Price Indexes, 135
- Convoyed sales, 163–164, 166–167,  
 182
- Copyright Act (1790), 88–89
- Copyright Office, Library of  
 Congress, 12
- Copyrights  
 audits of, 154, 160 (*see also*  
   Audits)  
 fair use doctrine, 89–90  
 licensing, 16  
 ownership rights and, 91–93  
 right of publicity and, 91–93

- rights of, 12, 88–89
- royalty rates (*see* Trademark and copyright royalty rates)
- terms of, 88
- works made for hire, 92
- Cornell University v. Hewlett-Packard Co.*, 169–173
- Corporate value of IP&IA, 4–5, 25–26, 95–96
- Cost approach, 52
- Creators, monopolies for, 29–31, 88
- Cross-licenses, 15
- Damages
  - patent infringement (*see* Future damages; Lost profits; Patent infringement damages)
  - for publicity rights, 86
  - royalty rates for valuation, 103
- Databases, stand-alone, 148
- Daubert v. Merrell Dow Pharmaceuticals*, 203
- Decipher software, 156–157
- Decision analysis
  - biases and, 78–79
  - decision alternatives, 57
  - decision trees for, 56 (*see also* Decision trees)
  - definition, 56
  - in litigation environment, 59
  - probabilities of consequences, 58, 72
  - as software-aided, 63
- Decision trees
  - Bayes' theorem in, 72–73
  - process of, 55–63
  - risk aversion in, 79
  - rolling back the tree, 60, 61
  - as unwieldy, 64–65, 66, 69
- Deere & Co. v. Int'l Harvester Co.*, 182, 187
- Digital Information Communications and Electronics (DICE) sector, 17–19
- Discounted cash flow (DCF) analysis, 32–33, 48, 75–76
- Discount rate
  - CAPM for, 37–39
  - rate of return for, 32, 33–36
  - risk and income valuation, 52
  - venture capital rates of return, 42–46
- Docketing, 147, 156
- DuPont and exclusivity, 21–22
- Dynamic hedging, 77, 78
- eBay inc. v. MercExchange LLC*
  - future damages, 176–177
  - injunctive relief, 29–30, 175–176, 193
  - post-judgment royalty rate, 192
- Electrical and energy royalty rates, 313–346
  - amorphous metal transformers, 313
  - battery, 314–317
  - battery charger, 220–221, 317–318
  - cable, 319–321
  - cable rehabilitation, 318–319
  - electrical grid-tie inverter, 322–323
  - electroconversion cell, 322
  - gasification technology, 323–324
  - hydro-air renewable power system, 324–325

## Electrical and energy royalty rates

*(Continued)*

lighting, 326–328

nuclear power pipe repairs,  
328–329photovoltaic solar products,  
221–222, 329–330

power conversion, 330–331

sun-tracking solar power system,  
331turbine noise cancellation  
technology, 331–332

ultracapacitor technology, 332

wind turbines, 333–344

zinc air fuel cell, 344–346

## Employees

contracts and IP audits, 154–155,  
158, 159–160

turnover and IP audits, 152, 161

Energy royalty rates. *See* Electrical  
and energy royalty rates

Enforcement of patents, 6, 186

Entire market value (EMV) rule  
apportionment products, 165*Bose Corp. v. JBL, Inc.*, 165, 173

complementary products, 165

*Cornell University v. Hewlett-  
Packard Co.*, 159–173

definition, 164

*Georgia-Pacific Corp. v.**United States Plywood Corp.*,  
166–168, 173*King Instruments Corp. v. Perego*,  
173lost profits or reasonable royalties,  
164*Lucent Technologies, Inc. v.**Gateway, Inc.*, 168–169, 173

Patent Reform Act (2007), 28–29

as reasonable royalties

methodology, 168–172

*(see also* Reasonable royalty  
rates)*Rite-Hite Corporation v. Kelley  
Company, Inc.*, 165, 167,  
170, 173royalty base vs. rate, 164–166,  
168, 169–170, 171, 172–173*State Indus., Inc. v. Mor-Flo  
Indus., Inc.*, 170, 172, 173

Equity cost of capital, 36, 41

Established royalty, 177–179, 199

Event-driven audits, 151–152

Exclusivity

copyrights, 12, 88–89, 92

*Georgia-Pacific* nature of license,  
179–180

invention monopolies, 29–31, 88

IP audits, 154

post-judgment license and, 195,  
198royalty rates and, 20–22, 195,  
198Expected cash flow approach,  
34–35, 37

Expected inflation, 33, 34

Exploitation

multiple entities of, 91

new exploitations as new  
properties, 83–84physical vs. intellectual property,  
82

reasonable exploitations, 86–87

of trademarks, 87

Fair use doctrine, 89–90

*Fonar Corp. v. General Electric  
Co.*, 170

- Food and Drug Administration (FDA), 46–49
- FoundationIP software, 156
- Future damages, 175–188
  - date of hypothetical negotiation, 187–188
  - eBay Inc. v. MercExchange LLC*, 175–177
  - future lost profits, 188
  - Georgia-Pacific* to determine, 177–188 (see also *Georgia-Pacific Corp. v. United States Plywood Corp.*)
  - implementation optimization and, 198
  - injunctive relief and, 175, 188
- Future volatility, 77
- Fuzzy logic, 63
- Georgia-Pacific Corp. v. United States Plywood Corp.*
  - factor 1,2: established royalty, 177–179
  - factor 3: nature of license, 179–180
  - factor 4: patent monopoly, 180–181
  - factor 5: licensor-licensee relationship, 181
  - factor 6: conveyed or collateral sales, 182
  - factor 7: duration or term, 182–183
  - factor 8: profit expectations, 183
  - factor 9: innovation level, 183–184
  - factor 10: embodiment level, 184
  - factor 11: infringer use of, 184–185
  - factor 12,13: profit allocations, 185
  - factor 14: expert opinion, 185
  - factor 15: virtual transaction, 186–188
  - post-judgment royalty rate, 194
  - for reasonable royalty rate, 166–168, 173
  - Georgia-Pacific Corp. v. U.S. Plywood-Champion Papers, Inc.*
    - for reasonable royalty rate, 28
  - Google and fair use, 90
  - Government and licensing, 18–19, 157
  - Hanson v. Alpine Valley Ski Area, Inc.*, 178
- Healthcare
  - healthcare companies' reasons for licensing, 17–19
  - medical device industry, license fees, 112–113
  - medical device industry, royalty rates, 111–112
  - medical diagnosis and Bayes' theorem, 74–75
  - pharmaceutical royalty rates (see Pharmaceutical royalty rates)
- Historical volatility, 77
- Implementation optimization, 189, 195–198
- Income approach, 32, 33, 52
- Industrial sector, and licensing, 18–19

- Injunctions for patent infringement  
*eBay Inc. v. MercExchange LLC*, 29–30, 175–177, 192–193  
 future damages and, 175, 188  
 (see also Future damages)  
 implementation optimization and, 189, 195–198  
 Patent Reform Act (2007), 29–31  
 post-judgment royalty rates and, 189, 192–194
- Intellectual property and intangible assets (IP&IA)  
 as corporate value, 4–5, 25–26, 95–96  
 due diligence, 151  
 intangible vs. tangible assets, 4–5, 26, 144  
 new exploitations as new property, 83–84  
 reasons for developing, 18–24  
 soft intangible properties, 83  
 volatility of, 95–99
- International Trademark Association (INTA), 90
- Inventions, monopolies for, 29–31, 88
- Invested capital (INCAP), 96
- Investigational new drug (IND), 47
- Joint ventures  
 auditing joint venture agreements, 155  
 as reason for licensing, 18–19
- Kalman v. Berlyn Corp.*, 170  
*King Instruments Corp. v. Perego*, 173
- Lanham Act (1946), 90  
*Let's Make a Deal* and Bayes' theorem, 73
- Library of Congress, 12
- Licensing. See also Royalty rates  
 audits of, 154–155 (see also Audits)  
 biotechnology license fees, 124–125, 128 (see also Biotechnology royalty rates)  
 as business strategy, 6, 17–19, 20–24, 114  
 of celebrity images, 25  
 Copyright Act and ownership, 91–92  
 cross-licenses, 15  
 exclusivity (see Exclusivity)  
 medical device license fees, 112–113  
 parties involved, 122, 128  
 patents, 18, 21 (see also Patent Reform Act [2007]; Patents)  
 pharmaceutical license fees, 124–125, 128 (see also Pharmaceutical royalty rates)  
 reasons for, 17–24  
 revenue from, 15–16  
 royalty misreporting (see Royalty misreporting)  
 royalty rates, 15, 20–24, 28–29 (see also Royalty rates)  
 software for, 156–157  
 sublicenses, 137, 139  
 technology, 16, 17, 21–24 (see also Technology royalty rates)  
 trademark and copyright, 16 (see also Trademark and copyright royalty rates)  
 25% rule, 203–205

- up-front license fees, 109–111, 112–113, 119–120, 124
- Litigation
  - litigation-based royalty rates, 178, 190, 198–202
  - Marilyn Monroe estate, 93
  - patent litigation venue, 27
  - “Risk Evaluation in Intellectual Property Litigation” (Victor), 59
  - 25% rule and, 205
- Long-Term Capital Management, 54, 80
- Lost profits
  - conveyed or collateral sales and, 163
  - future lost profits, 188
  - Patent Reform Act (2007), 29
  - reasonable royalty rate and, 177
- Lucent Technologies, Inc. v. Gateway, Inc.*, 168–169, 173
- Made for hire, 92
- Malkiel, Burton G., 67
- Management of IP assets. *See also* Audits
  - audit results mapped to strategy, 145–146, 158
  - benefits of, 149–150
  - as business strategy, 142–143, 149–150
  - databases, stand-alone, 148
  - docketing, 147, 149
  - management system capabilities, 148–150
  - shared directories, 147–148
  - software for, 155–157
  - spreadsheets, 147
  - tools for, 148
- Market approach, 52
- Markov, Andrei A., 66
- Markov chains, 66–70
- Marks. *See* Trademarks
- Medical device industry
  - license fees, 112–113
  - royalty rates, 111–112
- Medical diagnosis and Bayes’ theorem, 74–75
- Memoryless evolution, 67–68
- Memotech software, 156
- Meriwether, John, 54
- Merton, Robert C., 54, 77
- Metropolis, Nicolas, 64
- Milestones and benchmarks
  - Royalty Rates for Technology*, 115
  - unreported, 132, 133, 137
- Monetization. *See* Commercialization of intellectual property
- Monopolies, for creators, 29–31, 88
- Monroe, Marilyn, 93
- Monte Carlo techniques, 63–66, 69
- Morgenstern, Oskar, 55
- Mullins, David, 54
- Net present value (NPV), 75–76
- Network servers for IP management, 147–148
- New chemical entities (NCEs), 46–48
- New molecular entities (NMEs), 46–48
- Nodes (decision tree), 57–62
- Nonpracticing patent holders, 29–31, 193

- Ocean Tomo and intangible asset values, 4, 26, 142
- Option pricing models, 75–78
- Ownership, rights of
  - Copyright Act and, 91–93
  - defined in appraisal, 82
- Paice LLC v. Toyota Motor Corp.*, 189, 190–195
- Panduit Corp. v. Stahl Bros. Fibre Works, Inc.*, 178
- Paper Converting Machine Co. v. Magna-Graphics Corp.*, 170
- Partnerships, 18–19
- Patent infringement damages
  - assumptions in, 186, 188
  - eBay Inc. v. MercExchange LLC*, 29–30, 175–177, 192–193
  - future damages (*see* Future damages)
  - implementation optimization and, 189, 195–198
  - lost profits (*see* Lost profits)
  - Patent Reform Act (2007), 27–29, 31
  - post-judgment royalty rates, 189, 190–195
  - reasonable royalties (*see* Reasonable royalty rates)
- Patent Reform Act (2007), 25–31
  - corporate value of IP&IA, 4–5, 25–26, 95–96
  - entire market value rule (*see* Entire market value [EMV] rule)
  - injunctions for only competitors, 29–31
  - patent infringement damages, 27–29, 31
  - patent litigation venue, 27
- Patents
  - audits of, 153, 159 (*see also* Audits)
  - conveyed vs. collateral sales, 163–164
  - corporation-owned, 7–8
  - enforcement of, 6, 186
  - infringement damages (*see* Patent infringement damages)
  - licensing, 18, 21 (*see also* Licensing)
  - nonpracticing patent holders, 29–31, 193
  - patent families, 152
  - patent protection, 21
  - patent trolls, 176
  - practicing the patent, 30
  - relief from royalty method, 97–99 (*see also* Relief from royalty method)
  - rights and terms of, 6
  - software for, 156
  - technology classifications, 8
  - 25% rule, 203–205
  - valuation as options, 77–78
- Patent trolls, 176
- Patricia software, 156
- Pepsi and trade secrets, 14–15
- Pharmaceutical companies' reasons
  - for licensing, 17–19
- Pharmaceutical royalty rates, 121–128, 253–276
  - aldurazyme, 254–256
  - anti-hypertension therapy, 256–258
  - attention deficit hyperactivity disorder, 258–259
  - blood expander, 260–264
  - cancer, 264–268
  - corporate involvement, 122

- developmental stages of
  - technology, 126–128, 137, 253–254
- exclusivity and, 21–22 (*see also* Exclusivity)
- key technologies, 125–126, 127
- license fees, 124–125, 128
- neurodegenerative and psychiatric diseases therapy, 269–272
- pain management, 272–273
- per unit royalties, 123, 128
- probability of success, 45–49
- progesterone gel, 273–275
- royalty percentages, 122–124, 128, 253–254
- Royalty Rates for Pharmaceuticals & Biotechnology*, 21, 121, 253
- spleen tyrosine kinase (Syk) inhibitor, 275–276
- Present value, 32–36
- Pricing. *See also* Licensing; Royalty rates
  - arm's-length pricing, 136
  - option pricing models, 75–78
  - price volatility, 36
  - random walk, stock prices, 67
  - shadow pricing, 70–72
  - third-party pricing, 136
  - transfer prices, 136
  - walk-away price, 101
- Privacy
  - right of privacy, 84–85
  - right of publicity, 85–87, 90, 91–93
- Probability
  - Bayes' theorem, 72, 75
  - decision tree nodes, 58
  - Markov chains, 66–67, 68, 70
  - Monte Carlo, 64, 66
  - random walk theory, 67, 68
  - risk vs. uncertainty, 53–55
  - sensitivity analysis, 58, 61–62
  - of success, 37, 39, 45–49
  - transition probabilities, 68
  - What Are the Chances? Probability Made Clear* (Starbird), 74
- Public domain, 88, 90
- Publicity, right of
  - celebrity persona, 85–87 (*see also* Celebrity persona)
  - Lanham Act amendment, 90
  - photography, 91–93
- Random walk theory, 67, 68
- Rate. *See* Royalty rates
- Rates of return
  - as discount rate, 32, 33–36
  - elements of, 33
  - expected cash flow approach, 34–35
  - present value, 32–36
  - risk premium, 33–34
  - venture capital rates of return, 42–46
  - weighted average cost of capital (WACOC), 36
- Real rate of return, 33, 34
- Reasonable royalty rates
  - calculation of, 164–165
  - definition, 177
  - EMV as methodology, 168–172 (*see also* Entire market value [EMV] rule)
  - Georgia-Pacific* to determine, 166–168 (*see also* *Georgia-Pacific Corp. v. United States Plywood Corp.*)
  - lost profits vs., 177
  - Patent Reform Act (2007), 28–29

- Relief from royalty method
  - economic impact on IP&IA, 97–99
  - royalty rates for valuation, 103, 115
  - technology appraisal case study, 35–36, 37–40
- Research and development (R&D)
  - benchmark and milestone payments, 137
  - of licensee, 138
  - Patent Reform Act (2007), 29
  - as reason for licensing, 19
- ResQNet.com, Inc. v. Lansa, Inc.*, 190, 200–202
- Risk-adjusted cash flows, 32–50
  - build-up method, 41–42
  - capital asset pricing model (CAPM), 36–40
  - probability of success, 37, 39, 45–49
  - required rates of return, 33–36
  - venture capital rates of return, 42–46
- Risk and uncertainty, 51–80
  - Bayesian analysis, 63, 72–75
  - cognitive biases, 78–79
  - decision trees, 55–58
  - discount rate and, 52
  - dynamic hedging for risk removal, 77, 78
  - Markov chains, 66–70
  - memoryless evolution, 67–68
  - Monte Carlo techniques, 63–66
  - option pricing models, 75–78
  - random walk theory, 67, 68
  - “Risk Evaluation in Intellectual Property Litigation” (Victor), 59
  - rolling back the tree, 60, 61
  - shadow pricing, 70–72
  - systematic risk, 34, 36–37, 48
  - uncertainty vs. risk, 53–55
  - unsystematic risk, 34, 37, 48
- Risk aversion, 79
- Risk dread, 79
- Risk-free rate of return, 33, 34, 41, 42
- Risk premium, 33–34, 36, 41
- Risk-seeking behavior, 79
- Rite-Hite Corporation v. Kelley Company, Inc.*, 165, 167, 170, 173
- Rolling back the tree, 60, 61
- Royalty agreements
  - in audits, 155, 158–161
  - software management of, 156–157
- Royalty base
  - base vs. rate, 164–166, 168, 169–170, 171, 172–173
  - in royalty calculation, 166
  - 25% rule, 203–205
- Royalty income, 15–17, 20
- Royalty misreporting, 129–140. *See also* Audits
  - disallowed deductions, 138–139
  - how misreporting happens, 130–133
  - magnitude of underreporting, 130, 131
  - math errors, 133–134
  - questionable license interpretation, 139–140
  - royalty rate errors, 134–136
  - transfer prices, 136
  - unreported benchmarks and milestones, 137
  - unreported sales, 138
- Royalty rates, 103–114, 115–120. *See also* Licensing
  - base vs. rate, 164–166, 168, 169–170, 171, 172–173

- for biotechnology (*see* Biotechnology royalty rates)
- for copyrights (*see* Trademark and copyright royalty rates)
- determination of, 164–165 (*see also* Reasonable royalty rates)
- for electrical and energy (*see* Electrical and energy royalty rates)
- established royalty, 177–179, 199
- 5% royalty rate, 15, 105–107, 117–118
- future damages (*see* Future damages)
- key factors for setting, 20–24, 114
- license fees, 109–113, 119–120 (*see also* Licensing)
- litigation-based, 178, 190, 198–202
- for medical device industry, 111–112
- misreporting (*see* Royalty misreporting)
- Patent Reform Act (2007), 28–29
- per unit royalties, 107–108, 118–119, 120, 123
- for pharmaceuticals (*see* Pharmaceutical royalty rates)
- post-judgment rates, 189, 190–195
- profitability basis, 108–109, 124
- in royalty calculation, 166 (*see also* Reasonable royalty rates)
- Royalty Rates for Pharmaceuticals & Biotechnology*, 21, 121, 253
- Royalty Rates for Technology*, 104, 116, 207
- Royalty Rates for Trademarks and Copyrights*, 235
- running royalties (*see* Running royalties)
- for technology (*see* Technology royalty rates)
- for trademarks (*see* Trademark and copyright royalty rates)
- 25% rule, 203–205
- for valuation, 103, 115
- Rude v. Westcott*, 178, 200
- Running royalties
  - lump sum royalty vs., 169
  - pharmaceutical and biotechnology, 122
  - in settlement agreements, 199
  - technology, 109–110, 119
- S&P 500 and IP&IA value, 4–5, 26, 95–96
- Scholes, Myron, 54, 76
- Servers, for IP management, 147–148
- Service marks, 10, 154
- Settlement license agreements, 199. *See also* Litigation
- Shadow pricing, 70–72
- Shared directories for IP management, 147–148
- Simplification, numbers as, 56, 80
- Soft intangible properties, 83
- Software
  - audit software, 155–158
  - Bayes' theorem, 73
  - decision trees, 61, 63, 79
  - as intellectual property, 154, 160
  - Markov chains, 69
  - Monte Carlo, 66
  - risk aversion, 79
  - Spam Bayes program, 72
- Specific risk, 34

- Spreadsheets, for IP management, 147
- Stand-alone databases, 148
- Starbird, Michael, 74
- State Indus., Inc. v. Mor-Flo Indus., Inc.*, 170, 172, 173
- Sublicenses, 137, 139
- Success, probability of, 37, 39, 45–49
- Susan Maxwell v. J. Baker, Inc.*, 178–179
- Systematic risk, 34, 36–37, 48
  
- Tangible assets
  - intangible vs., 4–5, 26, 144
  - photograph copy, 92
- Technology royalty rates, 103–114, 115–120, 207–234
  - appraisal case study, 35–36, 37–40, 41–42, 42–46
  - automotive, 208–211
  - battery charger, 220–221 (*see also* Electrical and energy royalty rates)
  - biotechnology (*see* Biotechnology royalty rates)
  - broadband, 212–214, 279–280 (*see also* Telecommunications royalty rates)
  - chemical, 211–212
  - computer hardware, 216–218
  - computer software, 219–220
  - electronics, 222–223
  - 5% royalty rate, 105–106, 118
  - food and beverage, 224–225
  - industries included, 104, 116, 207–208
  - license fees, 109–111, 112–114, 119–120
  - licensing, 16, 17, 21–24
  - mechanical, 225–227
  - medical, 228–231
  - medical device, 111–115
  - network solutions, 214–216 (*see also* Telecommunications royalty rates)
  - per unit royalties, 107–108, 114, 118–119, 120
  - photography, 231–233
  - photovoltaic solar products, 221–222 (*see also* Electrical and energy royalty rates)
  - probability of success, 37, 45–49
  - profitability based, 108–109, 114
  - royalty percentages, 107, 117, 120
  - Royalty Rates for Technology*, 104, 116, 207
  - sports, 233–234
- Telecommunications royalty rates, 277–311
  - acoustics, 277–278
  - antenna, 278
  - broadband, 212–214, 279–280
  - cable transmission standards, 281–283
  - cellular 3G technology, 288–289
  - cellular CDMA technology, 290–293
  - cellular phone docking system, 283–286
  - cellular phone technology, 286–288
  - emergency communications, 293–294
  - encryption, 294–295
  - e-retailing, 295–297
  - Internet phone service, 310–311
  - Internet software, 297–298
  - long distance calling features, 298–299

- network access, 299
- network solutions, 214–216, 299–301
- smart phones, 302
- software, 302–303
- speech compression standards, 303–304
- telecommunications access
  - devices, 304–306
  - television transmission, 306–308
  - transceiver integrated circuit, 308
  - videoconferencing, 308–309
  - voice mail, 309–310
- Teller, Edward, 63
- Third-party pricing, 136
- Third-party rights, audits
  - identifying, 144, 152, 160
- Third-party royalties, examples of, 259
- Toyota Motor Corp., Paice LLC v.*, 189, 190–195
- Trademark and copyright royalty rates, 235–251
  - body armor, 236
  - cheese, 237–238
  - children’s entertainment, 238–240
  - cleaning products, 240–241
  - coffee, 241–242
  - comic characters, 250–251
  - electronics, 246–248
  - industries included, 235–236
  - jewelry, 243–244
  - mobile games, 244–246
  - tax preparation service, 248–249
  - tennis equipment, 249–250
- Trademarks
  - advertising and, 11–12
  - audits of, 154 (*see also* Audits)
  - brand loyalty and, 67–69
  - celebrity persona as, 87
  - common-law marks, 154
  - International Trademark Association (INTA), 90
  - Lanham Act (1946), 90
  - licensing, 16
  - rights of, 10
  - royalty rates (*see* Trademark and copyright royalty rates)
  - service marks, 10, 154
  - software for, 156
- Trade secrets
  - audits of, 153–154, 160 (*see also* Audits)
  - competitive advantage and, 13–14, 18
  - definitions, 12–14
  - valuation of, 14
- Transfer prices, 136
- Transition probabilities, 68
- Trolls, patent, 176
- Turnover of employees, and IP audits, 152, 161
- 25% rule, 203–205
- Ulam, Stanislaw, 63–64
- Uncertainty. *See also* Risk and uncertainty
  - Markov chains for, 68
  - option pricing models for, 75–76
  - risk plus, 63
  - risk vs., 53–55
- Uniloc USA, Inc. v. Microsoft Corporation*, 203, 204–205
- United States Patent and Trademark Office (USPTO), 6, 8
- Universities and licensing
  - reasons for licensing, 18–19
  - stage of development, 24, 127
  - unreported benchmarks and milestones, 137

- Unsystematic risk, 34, 37, 48
- Up-front license fees
  - medical device industry, 112–113
  - pharmaceuticals and biotechnology, 124
  - technology, 109–111, 119–120
- Valuation
  - assumptions in, 82, 83
  - of call on stock, 77
  - of commercialization, 32
  - decision making as, 55
  - definition, 82
  - of equity capital, 36
  - overview, 1
  - of patent as option, 77–78
  - present value, 32–36
  - royalty rates for, 103, 115
  - simplification and, 56, 80
  - technology appraisal case study, 35–36, 37–40, 41–42, 42–46
  - trademarks and brand loyalty, 67–69
  - of trade secrets, 14
  - 25% rule, 203–205
- Venture capital rates of return, 42–46
- Venue, patent litigation, 27
- Victor, Marc B., 59
- Virtual transactions, 82, 186–188
- Viscusi, W. Kip, 71
- Volatility
  - Black-Scholes option pricing model, 77, 78
  - IP&IA volatility, 95–99
  - price volatility, 38
- von Neumann, John, 55, 63
- Walk-away price, 101
- Weighted average cost of capital (WACOC), 36
- Wendt v. Host Int'l, Inc.*, 86–87
- White, Vanna, 86
- White v. Samsung Elec. Am., Inc.*, 86
- Works made for hire, 92
- WorldSuite software, 156